The Presence of Lung Cancer Affects SARS-CoV-2 Vaccine Uptake and Attitude in Chinese Patients: A Clinical Cross-Sectional Investigation

References

• Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J. 2020;43(4):328–333. doi:10.1016/j.bj.2020.04.007.
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. COVID-19 situation update of China as of October 3, 2022. 2022.
   Google Scholar
• WHO Coronavirus (COVID-19) Dashboard. 2022. [Last accessed 3 Oct 2022]. Available from: http://covid19.who.int
   Google Scholar
• Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, et al. Risk factors for coronavirus disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19). Eur J Cancer. 2020; 141:62–81. doi:10.1016/j.ejca.2020.09.035.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Whisenant JG, Huang L-C, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21(7):914–922. doi:10.1016/S1470-2045(20)30314-4.
   PubMed Web of Science ®Google Scholar
• Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–791. doi:10.1158/2159-8290.Cd-20-0422.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894–901. doi:10.1016/j.annonc.2020.03.296.
   PubMed Web of Science ®Google Scholar
• Mi Y-n, Huang T-t, Zhang J, X, Qin Q, Gong Y-x, Liu S-y, et al. Estimating the instant case fatality rate of COVID-19 in China. Int J Infect Dis. 2020; 97:1–6. doi:10.1016/j.ijid.2020.04.055.
   PubMed Web of Science ®Google Scholar
• Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. Int J Infect Dis. 2020; 101:138–148. doi:10.1016/j.ijid.2020.09.1464.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Center. 2022;2(1):1–9. doi:10.1016/j.jncc.2022.02.002.
   Google Scholar
• Morgan AJ, Poland GA. Edward Jenner and the discovery of vaccination–an appeal for the Edward Jenner Museum. Vaccine. 2013;31(43):4933–4934. doi:10.1016/j.vaccine.2013.07.046.
   PubMed Web of Science ®Google Scholar
• Malik JA, Agrewala JN. Future perspectives of emerging novel drug targets and immunotherapies to control drug addiction. Int Immunopharmacol. 2023; 119:110210. doi:10.1016/j.intimp.2023.110210.
   PubMed Web of Science ®Google Scholar
• Nagpal D, Nagpal S, Kaushik D, Kathuria H. Current clinical status of new COVID-19 vaccines and immunotherapy. Environ Sci Pollut Res Int. 2022;29(47):70772–70807. doi:10.1007/s11356-022-22661-1.
   PubMed Web of Science ®Google Scholar
• Duarte LF, Gálvez NMS, Iturriaga C, Melo-González F, Soto JA, Schultz BM, et al. Immune profile and clinical outcome of breakthrough cases after vaccination with an inactivated SARS-CoV-2 vaccine. Front Immunol. 2021; 12:742914. doi:10.3389/fimmu.2021.742914.
   PubMed Web of Science ®Google Scholar
• Asghar N, Mumtaz H, Syed AA, Eqbal F, Maharjan R, Bamboria A, et al. Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review. Immunol Med. 2022;45(4):225–237. doi:10.1080/25785826.2022.2068331.
   PubMedGoogle Scholar
• Malik JA, Aroosa M, Ahmed S, Shinde M, Alghamdi S, Almansour K, et al. SARS-CoV-2 vaccines: clinical endpoints and psychological perspectives: a literature review. J Infect Public Health. 2022;15(5):515–525. doi:10.1016/j.jiph.2022.03.017.
   PubMed Web of Science ®Google Scholar
• Valanparambil RM, Carlisle J, Linderman SL, Akthar A, Millett RL, Lai L, et al. Antibody response to COVID-19 mRNA vaccine in patients with lung cancer after primary immunization and booster: reactivity to the SARS-CoV-2 WT virus and omicron variant. J Clin Oncol. 2022;40(33):3808–3816. doi:10.1200/jco.21.02986.
   PubMed Web of Science ®Google Scholar
• Gounant V, Ferré VM, Soussi G, Charpentier C, Flament H, Fidouh N, et al. Efficacy of severe acute respiratory syndrome coronavirus-2 Vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. J Thorac Oncol. 2022;17(2):239–251. doi:10.1016/j.jtho.2021.10.015.
   PubMed Web of Science ®Google Scholar
• Malik JA, Ahmed S, Mir A, Shinde M, Bender O, Alshammari F, et al. The SARS-CoV-2 mutations versus vaccine effectiveness: new opportunities to new challenges. J Infect Public Health. 2022;15(2):228–240. doi:10.1016/j.jiph.2021.12.014.
   PubMed Web of Science ®Google Scholar
• Mack PC, Gomez JE, Rodilla AM, Carreño JM, Hsu CY, Rolfo C, et al. Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer. Cancer Cell. 2022;40(6):575–577. doi:10.1016/j.ccell.2022.04.012.
   PubMed Web of Science ®Google Scholar
• Hwang JK, Zhang T, Wang AZ, Li Z. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. J Hematol Oncol. 2021;14(1):38. doi:10.1186/s13045-021-01046-w.
   PubMed Web of Science ®Google Scholar
• Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021;18(5):313–319. doi:10.1038/s41571-021-00487-z.
   PubMed Web of Science ®Google Scholar
• MacDonald NE, Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161–4164. doi:10.1016/j.vaccine.2015.04.036.
   PubMed Web of Science ®Google Scholar
• Nguyen M, Bain N, Grech L, Choi T, Harris S, Chau H, et al. COVID-19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study. Asia-Pac J Clncl Oncology. 2022;18(6):570–577. doi:10.1111/ajco.13754.
   PubMed Web of Science ®Google Scholar
• Huang J, Chan SC, Ko S, Wang HHX, Yuan J, Xu W, et al. Factors associated with vaccination intention against the COVID-19 pandemic: a global population-based study. Vaccines. 2022;10(9):1539. doi:10.3390/vaccines10091539.
   Web of Science ®Google Scholar
• Hong J, Xu XW, Yang J, Zheng J, Dai SM, Zhou J, et al. Knowledge about, attitude and acceptance towards, and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China: A cross-sectional survey. J Integr Med. 2022;20(1):34–44. doi:10.1016/j.joim.2021.10.004.
   PubMedGoogle Scholar
• Mejri N, Berrazega Y, Ouertani E, Rachdi H, Bohli M, Kochbati L, et al. Understanding COVID-19 vaccine hesitancy and resistance: another challenge in cancer patients. Support Care Cancer. 2022;30(1):289–293. doi:10.1007/s00520-021-06419-y.
   PubMed Web of Science ®Google Scholar
• Chan WL, Ho YT, Wong CK, Choi HC, Lam KO, Yuen KK, et al. Acceptance of COVID-19 Vaccination in Cancer Patients in Hong Kong: Approaches to Improve the Vaccination Rate. Vaccines (Basel). 2021;9(7):792. doi:10.3390/vaccines9070792.
   PubMed Web of Science ®Google Scholar
• Wong MCS, Wong ELY, Huang J, Cheung AWL, Law K, Chong MKC, et al. Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong. Vaccine. 2021;39(7):1148–1156. doi:10.1016/j.vaccine.2020.12.083.
   PubMed Web of Science ®Google Scholar
• Enticott J, Gill JS, Bacon SL, Lavoie KL, Epstein DS, Dawadi S, et al. Attitudes towards vaccines and intention to vaccinate against COVID-19: a cross-sectional analysis-implications for public health communications in Australia. BMJ Open. 2022;12(1):e057127. doi:10.1136/bmjopen-2021-057127.
   PubMed Web of Science ®Google Scholar
• Ruiz JB, Bell RA. Parental COVID-19 Vaccine Hesitancy in the United States. Public Health Rep. 2022;137(6):1162–1169. doi:10.1177/00333549221114346.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang L, Chen S, Lan X, Song M, Su R, et al. Hesitancy to receive the booster doses of COVID-19 vaccine among cancer patients in China: a multicenter cross-sectional survey - four PLADs, China, 2022. China CDC Wkly. 2023;5(10):223–228. doi:10.46234/ccdcw2023.041.
   PubMedGoogle Scholar
• Zhuang W, Zhang J, Wei P, Lan Z, Chen R, Zeng C, et al. Misconception contributed to COVID-19 vaccine hesitancy in patients with lung cancer or ground-glass opacity: a cross-sectional study of 324 Chinese patients. Hum Vaccin Immunother. 2021;17(12):5016–5023. doi:10.1080/21645515.2021.1992212.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang J, Su R, Du X, Wang Y, Chen S, et al. Concerns related to the interactions between COVID-19 vaccination and cancer/cancer treatment were barriers to complete primary vaccination series among Chinese cancer patients: a multicentre cross-sectional survey. Hum Vaccin Immunother. 2023;19(2):2222648. doi:10.1080/21645515.2023.2222648.
   PubMed Web of Science ®Google Scholar
• Barrière J, Gal J, Hoch B, Cassuto O, Leysalle A, Chamorey E, et al. Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey. Ann Oncol. 2021;32(5):673–674. doi:10.1016/j.annonc.2021.01.066.
   PubMed Web of Science ®Google Scholar
• Chun JY, Kim SI, Park EY, Park SY, Koh SJ, Cha Y, et al. Cancer patients’ willingness to take COVID-19 vaccination: a nationwide multicenter survey in Korea. Cancers. 2021;13(15):3883. doi:10.3390/cancers13153883.
   PubMed Web of Science ®Google Scholar
• Tsai R, Hervey J, Hoffman K, Wood J, Johnson J, Deighton D, et al. COVID-19 vaccine hesitancy and acceptance among individuals with cancer, autoimmune diseases, or other serious comorbid conditions: cross-sectional, internet-based survey. JMIR Public Health Surveill. 2022;8(1):e29872. doi:10.2196/29872.
   PubMedGoogle Scholar
• Han K, Francis MR, Zhang R, Wang Q, Xia A, Lu L, et al. Confidence, acceptance and willingness to pay for the COVID-19 Vaccine among migrants in Shanghai, China: a cross-sectional study. Vaccines . 2021;9(5):443. doi:10.3390/vaccines9050443.
   PubMed Web of Science ®Google Scholar
• Freeman D, Loe BS, Chadwick A, Vaccari C, Waite F, Rosebrock L, et al. COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. Psychol Med. 2022;52(14):3127–3141. doi:10.1017/s0033291720005188.
   PubMed Web of Science ®Google Scholar
• Lin Y, Hu Z, Zhao Q, Alias H, Danaee M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: a nationwide online survey in China. PLoS Negl Trop Dis. 2020;14(12):e0008961. doi:10.1371/journal.pntd.0008961.
   PubMed Web of Science ®Google Scholar
• Liu W, Wu Y, Yang R, Chen R, Huang Y, Zhao X, et al. COVID-19 vaccination status and hesitancy among breast cancer patients after two years of pandemic: a cross-sectional survey. Vaccines . 2022;10(9):1530. doi:10.3390/vaccines10091530.
   Web of Science ®Google Scholar
• Wang X, Shen M, Zhang Q, Wang X, Zhang H, Li T, et al. A web-based survey of SARS-CoV-2 vaccination and its adverse effects in Chinese postoperative patients with breast cancer: a cross-sectional study. Gland Surg. 2022;11(9):1497–1506. doi:10.21037/gs-22-454.
   PubMed Web of Science ®Google Scholar
• Xu Y, Li L, Li X, Li H, Song Y, Liu Y, et al. COVID-19 vaccination status, side effects, and perceptions among breast cancer survivors: a cross-sectional study in China. Front Public Health. 2023; 11:1119163. doi:10.3389/fpubh.2023.1119163.
   PubMed Web of Science ®Google Scholar
• Kanyike AM, Olum R, Kajjimu J, Ojilong D, Akech GM, Nassozi DR, et al. Acceptance of the coronavirus disease-2019 vaccine among medical students in Uganda. Trop Med Health. 2021;49(1):37. doi:10.1186/s41182-021-00331-1.
   PubMed Web of Science ®Google Scholar
• Zhang J, Dean J, Yin Y, Wang D, Sun Y, Zhao Z, et al. Determinants of COVID-19 vaccine acceptance and hesitancy: a health care student-based online survey in Northwest China. Front Public Health. 2021; 9:777565. doi:10.3389/fpubh.2021.777565.
   PubMed Web of Science ®Google Scholar
• Ahmad Malik J, Ahmed S, Shinde M, Almermesh MHS, Alghamdi S, Hussain A, et al. The impact of COVID-19 on comorbidities: a review of recent updates for combating it. Saudi J Biol Sci. 2022;29(5):3586–3599. doi:10.1016/j.sjbs.2022.02.006.
   PubMed Web of Science ®Google Scholar
• Albanghali M, Alghamdi S, Alzahrani M, Barakat B, Haseeb A, Malik JA, et al. Clinical characteristics and treatment outcomes of mild to moderate COVID-19 patients at Tertiary Care Hospital, Al Baha, Saudi Arabia: a single centre study. J Infect Public Health. 2022;15(3):331–337. doi:10.1016/j.jiph.2022.02.001.
   PubMed Web of Science ®Google Scholar
• China PsgotPsRo. COVID-19 vaccination (As of December 5). People’s Government of the People’ s Republic of China. 2022. [Last accessed 6 Dec 2022]. Available from: https://www.gov.cn/xinwen/2022-12/06/content_5730305.htm
   Google Scholar
• Harada D, Tamura T, Ninomiya K, Kubo T, Kuyama S, Tachibana S, et al. Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: a multicenter, prospective, observational, patient-reported outcome study. Thorac Cancer. 2023;14(3):231–236. doi:10.1111/1759-7714.14737.
   PubMed Web of Science ®Google Scholar
• Tamura T, Ninomiya K, Kubo T, Kuyama S, Tachibana S, Inoue K, et al. Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: a multicenter, prospective, observational study. Thorac Cancer. 2022;13(3):453–459. doi:10.1111/1759-7714.14281.
   PubMed Web of Science ®Google Scholar
• Mehta N, Sales RM, Babagbemi K, Levy AD, McGrath AL, Drotman M, et al. Unilateral axillary adenopathy in the setting of COVID-19 vaccine. Clin Imaging. 2021; 75:12–15. doi:10.1016/j.clinimag.2021.01.016.
   PubMed Web of Science ®Google Scholar
• Abouzid M, Ahmed AA, El-Sherif DM, Alonazi WB, Eatmann AI, Alshehri MM, et al. Attitudes toward Receiving COVID-19 Booster Dose in the Middle East and North Africa (MENA) Region: A Cross-Sectional Study of 3041 Fully Vaccinated Participants. Vaccines (Basel). 2022;10(8):1270. doi:10.3390/vaccines10081270.
   PubMed Web of Science ®Google Scholar
• Liu B, Zhang M, Li X, Liu L, Li Q, Liang Z, et al. Influence of epidemic situation on COVID-19 vaccination between urban and rural residents in China-Vietnam border area: A cross-sectional survey. PLoS One. 2022;17(7):e0270345. doi:10.1371/journal.pone.0270345.
   PubMed Web of Science ®Google Scholar
• Di Noia V, Renna D, Barberi V, Di Civita M, Riva F, Costantini G, et al. The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey. Eur J Cancer. 2021; 153:260–264. doi:10.1016/j.ejca.2021.05.006.
   PubMed Web of Science ®Google Scholar
• Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185(14):2422–2433.e13. doi:10.1016/j.cell.2022.06.005.
   PubMed Web of Science ®Google Scholar
• Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608(7923):603–608. doi:10.1038/s41586-022-05053-w.
   PubMed Web of Science ®Google Scholar
• Farooqi T, Malik JA, Mulla AH, Al Hagbani T, Almansour K, Ubaid MA, et al. An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies. J Infect Public Health. 2021;14(10):1299–1312. doi:10.1016/j.jiph.2021.08.014.
   PubMed Web of Science ®Google Scholar
• Malik JA, Ahmed S, Yaseen Z, Alanazi M, Alharby TN, Alshammari HA, et al. Association of SARS-CoV-2 and polypharmacy with gut-lung axis: from pathogenesis to treatment. ACS Omega. 2022;7(38):33651–33665. doi:10.1021/acsomega.2c02524.
   PubMedGoogle Scholar